The 15 Most-Prescribed Compounded Medications of 2026: Real Order Data From ScriptLinkRx Clinics

ScriptLinkRx is an ordering platform that connects licensed clinics and providers with licensed 503A and 503B compounding pharmacies. The ranking below reflects real cumulative order volume across the clinics ordering through the platform as of mid-2026 — not survey responses, prescriber sentiment, or search-trend estimates. It is a first-party view of what medical practices are actually ordering.

For providers evaluating a compounded-medication program, demand data drawn from real clinic ordering behavior carries a different weight than market projections. It shows which formulations have found durable clinical use across specialties, where category momentum is concentrated, and — read alongside the current regulatory picture — which products carry the most active compliance questions. This page presents the top 15, the methodology behind the ranking, and the regulatory backdrop every ordering clinic should understand in 2026.

Key Findings

• GLP-1 and metabolic combination products hold 6 of the top 15 positions, including the top four ranks — the clearest signal of where clinic compounding demand is concentrated in 2026.
• Recovery peptides and longevity or wellness compounds together fill most of the remaining positions, reflecting the expansion of compounded offerings beyond weight management.
• The single highest-ranked non-metabolic product is a recovery peptide, underscoring how peptide demand has grown even amid an unsettled regulatory picture.
• Sexual-wellness, hormone-and-growth, and skin-and-aesthetics compounds each appear in the lower half of the ranking, indicating a long tail of specialty demand rather than a second dominant category.
• No investigational compound appears anywhere in the ranking, by design — see the methodology and regulatory sections below.

Methodology

The unit of measure is cumulative order volume through the ScriptLinkRx platform as of mid-2026. Products are ranked by the total volume of orders placed by clinics for each formulation; the ranking is ordinal and does not publish unit counts, percentages, or a specific data window beyond "as of mid-2026."

Strength and dosage-form variants of the same underlying formulation are consolidated and counted as one product. For example, topical and injectable GHK-Cu are treated as a single product, and different concentrations of the same GLP-1 combination are merged. Combination products with a distinct additive composition (for instance, a GLP-1 paired with B6 versus the same GLP-1 paired with B12) are counted separately, because they represent different formulations that clinics order for different documented reasons.

Investigational compounds that are not eligible for compounding under sections 503A/503B of the FD&C Act were excluded from this ranking. This exclusion is why certain substances that generate substantial search interest — most notably the investigational triple agonist retatrutide — do not appear here at any rank.

The Top 15 at a Glance

GLP-1 & Metabolic

1. Tirzepatide with Pyridoxine (B6)

Tirzepatide is a dual GIP/GLP-1 receptor agonist; in this formulation it is compounded together with pyridoxine (vitamin B6). It is the highest-ranked compounded product on the platform, ordered heavily by weight-management, med spa, and metabolic clinics. The added B6 is presented by some compounders as an additive intended to support tolerability, though FDA has questioned blanket clinical rationale for such additives, and the individualized-need justification is the prescriber's responsibility. Regulatory note: FDA declared the tirzepatide shortage resolved in December 2024, so compounding is now governed by the "essentially a copy" framework, under which a 503A pharmacy generally needs a documented patient-specific clinical difference. See the tirzepatide with B6 page for detail.

2. Semaglutide with Pyridoxine (B6)

Semaglutide is a GLP-1 receptor agonist compounded here alongside pyridoxine (B6). It ranks second overall and is a mainstay of weight-management and metabolic practices. As with the tirzepatide combination, the B6 additive requires a provider-level clinical rationale rather than a blanket justification. Regulatory note: FDA declared the semaglutide shortage resolved in February 2025, ending the shortage exemption; compounded semaglutide is now subject to essentially-a-copy restrictions, and in 2026 FDA proposed excluding semaglutide from the 503B bulks list. Compounded semaglutide is not FDA-approved and is not equivalent to any branded product. See the semaglutide with B6 page.

3. Tirzepatide with Cyanocobalamin (B12)

This formulation pairs tirzepatide with cyanocobalamin (vitamin B12). It ranks third and is ordered by many of the same metabolic and aesthetic practices that order the B6 variant, with the B12 pairing marketed by some compounders in an energy-support framing. That framing is a clinical-rationale question for the prescriber, not an established outcome. Regulatory note: the same post-shortage essentially-a-copy analysis applies, and the compounded product is not FDA-approved. See the tirzepatide with B12 page.

4. Semaglutide with Cyanocobalamin (B12)

Semaglutide compounded with cyanocobalamin (B12) rounds out the top four, keeping all four leading positions within GLP-1 combination therapy. Clinic demand mirrors the semaglutide/B6 pattern, with the additive choice reflecting practice preference rather than a demonstrated clinical distinction. Regulatory note: as with all compounded semaglutide, the February 2025 shortage resolution and the essentially-a-copy framework apply, and FDA's 2026 proposal would keep semaglutide off the 503B bulks list. See the semaglutide with B12 page.

6. Tirzepatide with L-Carnitine

This product combines tirzepatide with L-carnitine, an amino-acid derivative involved in fatty-acid transport. It is ordered by metabolic and body-composition-focused clinics that prefer the carnitine pairing. As with every GLP-1 additive combination, the individualized clinical rationale for including L-carnitine rests with the prescriber, and FDA has signaled skepticism toward blanket additive justifications. Regulatory note: tirzepatide's shortage was resolved in December 2024, placing this product under standard essentially-a-copy rules. See the tirzepatide with L-carnitine page.

8. Tirzepatide with NAD+ and L-Carnitine

This is a triple-additive formulation combining tirzepatide with NAD+ and L-carnitine. It ranks eighth and is ordered by clinics building more elaborate metabolic and wellness programs around a GLP-1 base. The more additives a formulation includes, the heavier the documentation burden: each component's inclusion should be supported by a patient-specific clinical rationale rather than a standard recipe, consistent with FDA's stated concerns about additive combinations. Regulatory note: the tirzepatide base is subject to post-shortage essentially-a-copy analysis. See the tirzepatide with NAD+ and L-carnitine page.

Recovery Peptides

5. BPC-157

BPC-157 is a synthetic peptide fragment derived from a sequence identified in gastric juice, discussed almost entirely in a research and compounding context rather than any approved therapy. It is the highest-ranked non-metabolic product on the platform, ordered by peptide, sports-medicine, longevity, and regenerative-wellness clinics. Regulatory note: BPC-157 is not FDA-approved and has no USP monograph; it was removed from FDA's Category 2 bulk-substances table in April 2026 and is scheduled for Pharmacy Compounding Advisory Committee (PCAC) review in July 2026. Removal from Category 2 does not mean the substance is cleared or approved for compounding. See the BPC-157 provider page.

11. TB-500

TB-500 is a synthetic peptide related to thymosin beta-4, ordered by recovery- and performance-oriented clinics, often alongside BPC-157. It ranks eleventh. Regulatory note: TB-500 is not FDA-approved; like BPC-157, it was among the peptides FDA removed from Category 2 in April 2026 and is scheduled for PCAC review in July 2026. Its status remains unsettled — removal from the "do not compound" designation is not the same as authorization to compound, which would require a separate FDA decision. See the TB-500 provider page.

Longevity & Wellness

7. NAD+

NAD+ (nicotinamide adenine dinucleotide) is an endogenous coenzyme involved in cellular energy metabolism. In compounding it refers to preparations dispensed by licensed pharmacies, most commonly as IV, subcutaneous, or intranasal forms. It ranks seventh and is ordered predominantly by longevity, wellness, and integrative-medicine practices as well as some med spas and concierge clinics. Regulatory note: NAD+ is not an FDA-approved drug, and for parenteral preparations the key provider consideration is sterile-compounding quality — API source, potency, sterility, and endotoxin testing. See the compounded NAD+ page.

9. 5-Amino-1MQ

5-Amino-1MQ is a small-molecule research compound that acts as an inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). It is ordered as an oral capsule by longevity and metabolic-wellness clinics interested in NNMT-pathway modulation. It ranks ninth. Regulatory note: 5-Amino-1MQ is not FDA-approved and — importantly — was not among the peptides FDA removed from Category 2 in April 2026, placing it in a heightened-caution tier relative to the recovery peptides above it. Providers should treat its compounding status as unsettled and confirm lawful sourcing. See the 5-Amino-1MQ page.

14. Glutathione

Glutathione is an endogenous tripeptide antioxidant, compounded most often as IV, subcutaneous, or intranasal preparations. It ranks fourteenth and is ordered by wellness, aesthetic, and integrative practices as part of antioxidant-focused programs. Regulatory note: FDA has previously flagged quality issues in compounded glutathione, including endotoxin contamination events, which makes sterility and endotoxin testing the central sourcing questions for any glutathione preparation. See the compounded glutathione page.

Hormone & Growth

13. Sermorelin

Sermorelin is a growth-hormone-releasing hormone (GHRH) analog, ordered as a subcutaneous injection by hormone-optimization, age-management, and longevity practices. It ranks thirteenth. Regulatory note: the branded product Geref was FDA-approved and was discontinued in 2008 for commercial rather than safety reasons; today's compounded sermorelin is not FDA-approved and is not equivalent to any current branded product. Providers should evaluate the individualized clinical basis for use and confirm the compounding pharmacy's sterile-preparation credentials. See the sermorelin page.

Sexual Wellness

10. Oxytocin

Oxytocin is a peptide hormone with FDA-approved forms that exist for intravenous and obstetric use (for example, Pitocin). In compounding, it appears most often as intranasal sprays and troches ordered by sexual-wellness, relationship-health, and integrative practices. It ranks tenth. Regulatory note: the compounded intranasal and troche forms represent off-label uses distinct from the FDA-approved parenteral indication; the approved status of one route does not extend to compounded formulations for other uses. See the oxytocin page.

15. Bremelanotide (PT-141)

Bremelanotide, also known as PT-141, is a melanocortin-receptor agonist. The branded product Vyleesi was FDA-approved in 2019 for hypoactive sexual desire disorder in premenopausal women, delivered by subcutaneous autoinjector. Compounded bremelanotide, ordered by sexual-wellness clinics, ranks fifteenth. Regulatory note: compounded versions face essentially-a-copy analysis against the approved product, and uses in other populations or by other routes fall outside the approved indication. See the bremelanotide PT-141 page.

Skin & Aesthetics

12. GHK-Cu (Copper Peptide)

GHK-Cu is a copper-binding tripeptide used in both topical and injectable forms; consistent with the methodology above, the two forms are consolidated into a single ranked product. It ranks twelfth and is ordered by aesthetic and skin-focused practices, with topical use marketed in a cosmetic framing and injectable use raising distinct questions. Regulatory note: whether topical GHK-Cu is treated as a cosmetic or a drug depends on the claims made about it; injectable GHK-Cu was on FDA's Category 2 list and was among the peptides removed in April 2026, with PCAC review expected in 2027. See the GHK-Cu copper peptide page.

What the Data Says About Clinic Demand in 2026

GLP-1 combination products dominate clinic demand. Holding all four top positions and six of the top 15, tirzepatide- and semaglutide-based formulations are the center of gravity for compounded ordering in 2026. The pattern within that group is notable: clinics are not ordering a single "standard" GLP-1 preparation but a spread of additive combinations — B6, B12, L-carnitine, and multi-additive blends — each of which is treated as a distinct product because each requires its own patient-specific clinical rationale.

Peptide demand is evolving alongside FDA's 2026 regulatory activity. Recovery peptides BPC-157 and TB-500 both rank inside the top 15 even though their compounding status is actively in flux. FDA's April 2026 removal of several peptides from Category 2, and the July 2026 PCAC review of BPC-157 and TB-500, mean that the substances driving this demand sit at a genuine regulatory inflection point. Ordering clinics are, in effect, prescribing into a moving target — which is precisely why the removal-does-not-equal-authorization distinction matters so much here.

Longevity and wellness compounds are mainstreaming. NAD+, 5-Amino-1MQ, and glutathione appear across the ranking, and the clinics ordering them increasingly include not just dedicated longevity practices but med spas and primary-care-adjacent clinics broadening their service menus. The common thread among these items is that none is FDA-approved and most are parenteral, which shifts the provider's diligence from labeling questions toward sterile-compounding quality — sourcing, potency, sterility, and endotoxin testing.

The Regulatory Backdrop Providers Should Know

Post-shortage GLP-1 compounding operates under tighter limits than it did during the shortages. FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, ending the shortage exemption that had allowed broad compounding of both. Compounded semaglutide and tirzepatide are now subject to the "essentially a copy" restriction, under which a 503A pharmacy generally needs a documented patient-specific clinical difference from the approved product. In 2026, FDA further proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list. None of these compounded products is FDA-approved or equivalent to its branded counterpart.

The 2026 peptide picture is defined by FDA's Category 2 removals and the PCAC timeline. In April 2026, FDA removed a set of peptides — including BPC-157, TB-500, and injectable GHK-Cu — from Category 2 of its 503A bulk-substances list, and scheduled Pharmacy Compounding Advisory Committee review of several, with BPC-157 and TB-500 set for July 2026 and GHK-Cu expected in 2027. Providers should read these developments carefully: removal from Category 2 lifts an explicit "do not compound" designation but does not place a substance on the authorized 503A bulks list, and it does not mean the peptide is cleared or approved for compounding.

Finally, the investigational-exclusion in this ranking is a compliance point, not an omission. Substances that are not eligible for compounding under sections 503A/503B — most prominently the investigational triple agonist retatrutide, which has no approved version, no USP monograph, and no place on the 503A bulks list — were excluded by design. FDA has issued warning letters to sellers of compounded retatrutide, and the Alliance for Pharmacy Compounding has stated that compounders have no legal grounds to compound it. Providers weighing this class should review the retatrutide regulatory status before engaging with any offer to supply it.

How Clinics Order Compounded Medications Through ScriptLinkRx

Licensed clinics and providers order compounded medications through platforms like ScriptLinkRx, which connects practices with licensed 503A and 503B compounding pharmacies and centralizes product selection, prescriber management, and order tracking in one place. Providers evaluating a compounded-medication program can request a demo to see how ordering works.

Cite This Data

The ScriptLinkRx Compounded Medication Demand Ranking may be republished with attribution and a link back to this page. When citing this ranking, please use the following line:

Source: ScriptLinkRx Compounded Medication Demand Ranking, 2026 — scriptlinkrx.com/blog/most-prescribed-compounded-medications

Frequently Asked Questions

What is the most prescribed compounded medication in 2026?

Based on cumulative order volume across clinics ordering through ScriptLinkRx as of mid-2026, the most-prescribed compounded product is tirzepatide compounded with pyridoxine (B6), a GLP-1 combination ordered heavily by weight-management and metabolic practices. The top four positions are all GLP-1 combination formulations.

What compounded products do med spas order most?

Med spas concentrate their ordering in GLP-1 metabolic combinations (tirzepatide- and semaglutide-based formulations with additives such as B6, B12, or L-carnitine) and, increasingly, in longevity and wellness compounds such as NAD+ and glutathione, along with recovery peptides. The exact menu varies by state scope-of-practice rules and each clinic's clinical model.

Are compounded GLP-1s still available after the shortages ended?

The regulatory basis for compounding them changed after the shortages ended. FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, which ended the shortage exemption. Compounding these GLP-1s is now governed by the "essentially a copy" framework, under which a 503A pharmacy generally needs a documented patient-specific clinical difference from the approved product. These compounded products remain in active clinic demand but are not FDA-approved and are not equivalent to branded products.

Why isn't retatrutide in the ranking?

Retatrutide is an investigational triple agonist that is not FDA-approved for any use, has no USP monograph, and is not on the 503A bulks list, making it ineligible for compounding under sections 503A/503B. It was excluded from this ranking on that basis, consistent with the methodology.

Sources

• FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List — FDA
• List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B — Federal Register (May 1, 2026)
• List of Bulk Drug Substances Under Section 503B; Extension of Comment Period — Federal Register (June 26, 2026)
• FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize — FDA
• Declaratory Order: Resolution of Shortages of Semaglutide Injection Products — FDA
• FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — FDA